Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT
阿仑单抗和CXCL9水平可预测减低强度预处理造血干细胞移植后持续植入的可能性。
期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2022009478
Geerlinks, Ashley V; Scull, Brooks; Krupski, Christa; Fleischmann, Ryan; Pulsipher, Michael A; Eapen, Mary; Connelly, James A; Bollard, Catherine M; Pai, Sung-Yun; Duncan, Christine N; Kean, Leslie S; Baker, K Scott; Burroughs, Lauri M; Andolina, Jeffrey R; Shenoy, Shalini; Roehrs, Philip; Hanna, Rabi; Talano, Julie-An; Schultz, Kirk R; Stenger, Elizabeth O; Lin, Howard; Zoref-Lorenz, Adi; McClain, Kenneth L; Jordan, Michael B; Man, Tsz-Kwong; Allen, Carl E; Marsh, Rebecca A